Cancer virotherapy has high potential in China

(firmenpresse) - As one of the highest achievements of Latvia with high export potential to China, cancer virotherapy was mentioned during the "16+1 Summit" held in Riga last week.

Chinese Premier Li Keqiang addressed the Sixth China and Central and Eastern European (CEE) Countries Economic and Trade Forum in Riga. Latvia has been entrusted with the organisation of key events in cooperation between Central and Eastern European countries and China - the "16+1 Summit" and related side events – a business forum, a national coordinators’ meeting, a seminar of think tanks – as well as the first 16+1 Transport Ministers' meeting.

The 16+1 format is an initiative by the People’s Republic of China aimed at intensifying and expanding cooperation with 11 EU Member States and 5 Balkan countries (Albania, Bosnia and Herzegovina, Bulgaria, Croatia, the Czech Republic, Estonia, Hungary, Latvia, Lithuania, Montenegro, Poland, Romania, Serbia, Slovakia, Slovenia, Macedonia) in the fields of investments, transport, finance, science, education, and culture. In the framework of the initiative, China has defined three potential priority areas for economic cooperation: infrastructure, high technologies, and green technologies.

Cancer virotherapy is a cancer treatment using a virus that finds and destroys malignant cells in the human body. This kind of cancer treatment, also called oncolytic virotherapy, is evidence based and recognised as safe and effective therapy. A study published by Melanoma research suggests that a significant number of melanoma patients would benefit from prolonging the survival with oncolytic virotherapy treatment, moreover this can be achieved without serious side effects.

The first cancer virotherapy medicine was approved for melanoma treatment in 2004 by State Agency of Medicines of Latvia, EU member state. This year cancer virotherapy medicine received the grant from European Commission in order to initiate the commercialization in the EU markets. Cancer virotherapy medicine is manufactured, developed and promoted wordwide by Rigvir holding.

Weitere Infos zu dieser Pressemeldung:

Themen in dieser Pressemitteilung:


Unternehmensinformation / Kurzprofil:
PresseKontakt / Agentur:
Bereitgestellt von Benutzer: RealWire
Datum: 09.11.2016 - 13:21 Uhr
Sprache: Deutsch
News-ID 505802
Anzahl Zeichen: 2132

contact information:
Contact person: Samantha Sharp
Town:

Lincoln

Phone: +44 (0)1522 883 60

Kategorie:

Healthcare & Medical

Typ of Press Release: bitte
type of sending: Veröffentlichung

Diese Pressemitteilung wurde bisher 648 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Cancer virotherapy has high potential in China"
steht unter der journalistisch-redaktionellen Verantwortung von

RealWire (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Speedcast Delivers First Live Deployment for OneWeb’s Maritime LEO Service ...

Speedcast Delivers First Live Deployment for OneWeb’s Maritime LEO Service Maritime customer installation completed following successful sea trials of OneWeb LEO connectivity service Oslo, Norway — June 6, 2023 — Speedcast, a leading comm ...

Infinigate Group Appoints Simon England as Chief Growth Officer ...

Infinigate Group Appoints Simon England as Chief Growth Officer The Infinigate Group, following another year of double-digit growth, has appointed Simon England, former CEO of the Nuvias Group, as its Chief Growth Officer, to orchestrate the ongoi ...

neXat expands further East with KT SAT partnership ...

17 May 2023 – neXat has entered a partnership with KT SAT to offer the South Korean satellite operator a full suite of managed services and gain access to its coverage in Asia. KT SAT – a subsidiary of KT Corporation and one of South Korea’ ...

Alle Meldungen von RealWire